22
May

Rivals Novartis and Boehringer Ingelheim are touting positive results for their combination COPD treatments, duking it out with GlaxoSmithKline for dominance of a market that could reach $14 billion by 2018.

…read more

Source: Novartis, Boehringer vie for COPD market share with combo meds

    

0 No comments